Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423649 | 1.00 | CA2 (0.45) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL1120219 | 0.83 | CA1 (0.44) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL1120216 | 0.83 | CA1 (0.44) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL513627 | 0.74 | PPARG (0.47) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL513626 | 0.74 | PPARG (0.47) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL5973925 | 0.74 | PPARG (0.47) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL4632246 | 0.73 | CA2 (0.46) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL4632241 | 0.73 | CA2 (0.46) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL9598177 | 0.73 | CA1 (0.46) | CA2CA1PRSS1PRSS2PRSS3 | |
| SCHEMBL7119214 | 0.73 | CA2 (0.54) | CA2CA1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | NEOBIOTICS AB (SE) | 2010-09-30 | — | — | US | disclosed |
| US-7691805-B2 | Antimicrobial compounds | NEOBIOTICS AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | NEOBIOTICS AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | NEOBIOTICS AB (SE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116327-A1 | Dipeptide derivatives with active agents to formulate one composition to reduce, eliminate more than one microorganism; effect against a broad spectrum of microorganisms; mechanism of action on pathogen may be on a basic level; low probability for developing resistance | ARG1, ARGLU1, VIP | CA2 1411/4885CA1 789/4885PRSS1 536/4885 |
| US-20080255055-A1 | Use of Derivatives of Dipeptides for the Manufacture of of a Medicament for the Treamtent of Microbial Infections | VIP, ARG1, PEPD | CA2 1730/4885CA1 898/4885PRSS1 538/4885 |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | VIP, NGLY1, ARG1 | CA2 3516/4885CA1 4648/4885PRSS1 1430/4885 |
| US-20100247648-A1 | ANTIMICROBIAL COMPOUNDS | ARG1, C1R, ARG2 | CA2 2935/4885CA1 3619/4885PRSS1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.